NDAINJECTIONINJECTABLE
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPRAM (doxapram hydrochloride) is a small-molecule respiratory stimulant administered by injection used to treat respiratory depression and apnea. It works as a central nervous system stimulant to increase breathing rate and depth in patients with compromised respiratory function.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a consolidating market and potential team restructuring or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DOPRAM shows zero linked job openings, reflecting its mature, legacy product status with limited growth opportunities. Career trajectory on this product favors operational and efficiency-focused roles over business development or launch management.
Brand ManagerField Sales Representative
Worked on DOPRAM at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.